Serenoa repens (Permixon®)
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Serenoa repens (Permixon®)1 has been available for several years for the treatment of men with benign prostatic hyperplasia (BPH). The drug is the n-hexane lipidosterolic extract of the dwarf American palm (also known as Serenoa repens ) and is a complex mixture of various compounds. A number of pharmacodynamic effects have been demonstrated with the lipidosterolic extract of Serenoa repens (LSESR), suggesting multiple mechanisms of action including in vitro inhibition of both type 1 and type 2 isoenzymes of 5α-reductase and interference with binding of dihydrotestosterone to cytosolic androgen receptors in prostate cells.
In controlled clinical trials in men with BPH, oral administration of Serenoa repens 160mg twice daily for 1 to 3 months was generally superior to placebo in improving subjective symptoms, such as dysuria, as well as objective parameters. The frequency of nocturia was reduced by 33 to 74%, while urinary frequency during the day decreased by 11 to 43% and peak urinary flow rate increased by 26 to 50% with Serenoa repens. Corresponding values for placebo were 13 to 39%, 1 to 29% and 2 to 35%. The only large comparative trial conducted to date, in which >1000 men with moderate BPH were randomised to receive Serenoa repens 160mg twice daily or finasteride 5mg once daily for 6 months, demonstrated similar efficacy between the two drugs. No statistically significant difference was demonstrated between treatment groups for improvement in patient self-rated quality-of-life scores and the primary end-point of objective symptom score; International Prostate Symptom Score improved by 37% with Serenoa repens compared with 39% with finasteride. In much smaller comparative trials, few significant differences were demonstrated between Serenoa repens and α1-receptor antagonists, and larger randomised trials of adequate duration are required to better compare the clinical efficacy of these drugs. The most frequently reported adverse events in clinical trials with Serenoa repens have been minor gastrointestinal problems (e.g. nausea and abdominal pain).
In conclusion, Serenoa repens is well tolerated and has greater efficacy than placebo and similar efficacy to finasteride in improving symptoms in men with BPH. Although there is a need for further comparative studies, particularly with α1-receptor antagonists, available data indicate that Serenoa repens is a useful alternative to α1-receptor antagonists and finasteride in the treatment of men with BPH.
The precise mechanism of action of Serenoa repens has not been fully elucidated; however, important in vitro effects of the lipidosterolic extract of Serenoa repens (LSESR) include inhibition of 5α-reductase, the enzyme responsible for conversion of testosterone to dihydrotestosterone (DHT), and inhibition of binding of DHT to androgen receptors in the cytosolic component of prostate cells. Two 5α-reductase isoenzymes, type 1 and 2, appear to be expressed by cultured human prostate cells. Although there is some controversy whether the type 1 isoenzyme is expressed, it is generally agreed that the type 2 isoenzyme predominates. LSESR has been shown to inhibit both isoenzymes in a eukaryotic expression system, whereas finasteride primarily inhibits 5α-reductase type 2. LSESR also inhibited binding of the ligand [ H]methyltrienolone to androgen receptors in the cytosolic component of rat prostate cells and inhibited binding of [ H]DHT to its receptor in human foreskin fibroblasts.
Data from other in vitro studies and in vivo trials conducted in various animal models suggest additional mechanisms by which the drug may exert its effects. These include inhibition of prolactin- and growth factor-induced prostatic cell proliferation, an antioedematous effect and interference with mediators of inflammation.
Studies in men with benign prostatic hyperplasia (BPH) receiving Serenoa repens 320 mg/day for 3 months also suggest an antiestrogenic effect of the drug, and a comparative trial demonstrated reductions in prostatic tissue levels of DHT similar to those observed with finasteride 5 mg/day.
Limited pharmacokinetic data are available for Serenoa repens, primarily because the drug is a complex mixture of several compounds. In healthy young men, mean peak plasma drug concentration (second component; retention time 26.4 minutes on high performance liquid chromatography assay) was 2.6 mg/L and time to achieve peak concentration was 1.5 hours after oral administration of Serenoa repens 320mg. Elimination half-life was 1.9 hours and mean value of area under the concentration versus time curve was 8.2 mg/L • h. Tissue distribution studies in the rat indicate that the drug achieved higher concentrations in the prostate gland than the liver or genitourinary tissues other than the prostate.
The effects of Serenoa repens 160mg twice daily on urinary frequency and peak urinary flow rate were superior to placebo in 3 of 4 larger (i.e. >50 patients) controlled clinical trials lasting 1 to 3 months in men with BPH. Serenoa repens was associated with reductions in urinary frequency at night ranging from 33 to 74% (13 to 39% with placebo) and urinary frequency during the day ranging from 11 to 43% (1 to 29% with placebo); peak urinary flow rate was increased by 26 to 50% (2 to 35% with placebo) in placebo-controlled trials. Some studies evaluated additional parameters and demonstrated that Serenoa repens was more effective than placebo in improving dysuria (difficult or painful urination), reducing postmicturition residual urinary volume and improving subjective symptoms of BPH according to patient and physician global assessment.
Clinical efficacy of Serenoa repens 160mg twice daily was compared with that of finasteride 5mg once daily for 6 months in a large randomised double-blind study. The study was conducted in 9 European countries and is the largest international trial comparing 2 drugs in the treatment of men with BPH. Intention-to-treat analysis included 1069 men with moderate BPH and demonstrated similar results between treatment groups. At the end of the treatment period, symptoms [as assessed using the well-accepted International Prostate Symptom Score (I-PSS)] were reduced by 37% among Serenoa repens recipients compared with 39% among finasteride recipients, and the difference between treatment groups was not statistically significant. A marked improvement in patient self-rated quality-of-life scores was noted with both Serenoa repens and finasteride (69 vs 73%; no statistically significant difference between groups). Results of a separate questionnaire demonstrated that Serenoa repens produced a modest improvement in sexual function score, whereas a deterioration was reported with finasteride, and the difference between treatment groups achieved statistical significance. Both drugs improved peak urinary flow rates and reduced prostate volume, although changes were significantly greater with finasteride. However, the proportion of patients with a 30% or 3 ml/sec increase in peak urinary flow rate was similar between treatment groups. Unlike finasteride, Serenoa repens did not significantly affect serum prostate specific antigen (PSA) levels.
In two smaller comparative trials, Serenoa repens 160mg twice daily and α1-receptor antagonists improved overall symptoms, reduced urinary frequency and postmicturition residual urine volume and increased urinary flow rate. In general, clinical efficacy tended to favour the α1-receptor antagonists (alfuzosin 2.5mg 3 times daily and prazosin titrated to 2mg every 12 hours); however, few significant differences were observed between treatment groups. Moreover, studies included relatively small numbers of patients and one of the trials was only 3 weeks in duration.
In general, Serenoa repens is well tolerated, with only 2% of patients spontaneously reporting adverse events in a large noncomparative trial of 500 men with BPH receiving the drug for 3 months. Similar results were noted in smaller placebo-controlled trials, and discontinuation of Serenoa repens because of poor tolerability occurred only rarely. The most common adverse events in clinical trials have been minor gastrointestinal complaints, such as nausea and abdominal pain. In a large comparative trial with finasteride, Serenoa repens tended to be associated with a higher incidence of hypertension, headache, urinary retention and back pain, whereas gastrointestinal complaints, impotence, dysuria and decreased libido tended to be more frequently reported among men receiving finasteride. Clinically significant changes in laboratory parameters did not occur with Serenoa repens in clinical trials.
Dosage and Administration
For the treatment of men with BPH the recommended dosage of Serenoa repens is 160mg twice daily by oral administration. The drug should be taken with morning and evening meals to minimise possible gastrointestinal disturbances.
- Benard P, Cousse H, Chevalier G. Distribution study of radioactivity in rats after oral administration of lipidosterolic extract of Serenoa repens (Permixon®) supplemented with [1-14C] lauric acid, [1-14C] oleic acid or [4-14C] beta-sitosterol. Eur J Drug Metab Pharmacokinet. In press
- Fitzpatrick, J.M., Lynch, T.H. (1995) Phytotherapeutic agents in the management of symptomatic benign prostatic hyperplasia. Urol Clin North Am 22: pp. 407-12
- Neuzil, E., Cousse, H. (1993) The Saw palmetto Serenoa repens: botanical and chemical aspects. Bull Soc Pharm Bordeaux 132: pp. 121-41
- Raynaud J-P. Permixonα1® an overview of its pharmacological activities as regards medical treatment of benign prostatic hypertrophy (BPH). In: Dimopoulos CA, Di Silverio F, editors. BPH: From molecular biology to patient relief. Proceedings of the satellite symposium held during the 4th Mediterranean Congress of Urology; 1995 Sep 6-10; Rhodes. Bologna: Monduzzi Editore, 1996: 57-69
- Isaacs, J.T., Brendler, C.B., Walsh, P.C. (1983) Changes in the metabolism of dihydrotestosterone in the hyperplastic human prostate. J Clin Endocrinol Metab 56: pp. 139-46 CrossRef
- Imperato-McGinley, G., Gautier, T., Zirinsky, K. (1992) Prostate visualisation studies in male homozygous and heterozygous for 5α-reductase deficiency. J Clin Endocrinol Metab 75: pp. 1022-6 CrossRef
- Bruchovsky, N. (1971) Comparison of the metabolites found in rat prostate following the in vivo administration of 7 natural andro-gens. Endocrinology 89: pp. 1212-8 CrossRef
- Sitteree, P.K., Wilson, J.D. (1970) Dihydrotestosterone of prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic state of man. J Clin Invest 49: pp. 1737-45 CrossRef
- Walsh, P.C., Hutchins, G.M., Ewing, L.L. (1983) Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supranormal. J Clin Invest 72: pp. 1772-7 CrossRef
- Délos, S., Iehlé, C., Martin, P.M. (1994) Inhibition of the activity of ‘basic’ 5 α-reductase (type 1) detected in DU 145 cells and expressed in insect cells. J Steroid Biochem Mol Biol 48: pp. 347-52 CrossRef
- Iehlé, C., Délos, S., Guirou, O. (1995) Human prostatic steroid 5α-reductase isoforms — a comparative study of selective inhibitors. J Steroid Biochem Mol Biol 54: pp. 273-9 CrossRef
- Strauch, G., Perles, P., Vergult, G. (1994) Comparison of finasteride (Proscar®) and Serenoa repens (Permixon®) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol 26: pp. 247-52
- Briley, M., Carilla, E., Roger, A. (1985) A new treatment of prostatic hyperplasia, Permixon® has antiandrogen effects at two complementary levels. New Trends Androlog Sci 1: pp. 24-6
- Carilla, E., Briley, M., Fauran, F. (1984) Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem 20: pp. 521-3 CrossRef
- Carilla E, Roger A, Briley M, et al. The lipido-sterolic extract of Serenoa repens B: new treatment of prostatic hyperplasia, with anti-androgen effects at two complementary levels. Excerpta Medica 1986: 216-23
- Sultan, C., Terraza, A., Devillier, C. (1984) Inhibition of androgen metabolism and binding by a liposterolic extract of “Serenoa Repens B” in human foreskin fibroblasts. J Steroid Biochem 20: pp. 515-9 CrossRef
- Sultan C, Terraza A, Carilla E, et al. Anti-androgenic effects of Permixon: in vitro studies. New trends in BPH etiopathogen-esis. Proceedings of the International Workshop in Urology; 1987 Jul 22-25; Cannes, Rome; Acta Medica, 1988: 239-246.
- Farnsworth WE. PermixonR: antagonist of prolactin (PRL) action on the prostate [abstract no. 749]. 73rd Annual Meeting of the Endocrine Society, Washington, USA.
- Vacher, P., Prevarskaya, N., Skryma, R. (1995) The lipidosterolic extract from Serenoa repens interferes with prolactin receptor signal transduction. J Biomed Sci 2: pp. 357-65 CrossRef
- Paubert-Braquet M, Cousse H, Raynaud JP, et al. Effect of the lipidic Serenoa repens extract (PermixonR) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukotrienes and Medicine. In press
- Ragab A, Ragab-Thomas JMF, Delhon A, et al. Effects of Per-mixonR (Sereprostat® in Spain) on phospholipase A2 activity and on arachidonic acid metabolism in cultured prostatic cells. New trends in BPH etiopathogenesis 1987: 293-6
- Crastes de Paulet A, Damon M, Le Doucen C, et al. Anti-inflammatory and antiagregant activities of a lipido-sterolic extract from Serenoa repens on human neutrophiles and on human platelets models. Pierre Fabre Médicaments. (Data on file)
- Paubert Braquet, M., Janssen, D.H., Servent, N. (1995) Permixon® [lipido sterolic extract of Serenoa repens (LSESr)] inhibits b-FGF- and EGF-induced proliferation of human prostate or-ganotypic cell lines [abstract]. Pharmacol Res 31: pp. 69 CrossRef
- Silverio, F., Sciarr, A., D’Eramo, G. (1996) Response of tissue androgen and epidermal growth factor concentrations to the long-term administration of Serenoa repens (PermixonR), finasteride and flutamide to BPH patients. Eur Urol 30: pp. 96
- Tarayre, J.P., Delhon, A., Lauressergues, H. (1983) Anti-edematous action of a hexane extract of the stone fruit of Serenoa repens Bartr [in French]. Ann Pharm Fr 41: pp. 559-70
- Silverio, F., D’Eramo, G., Lubrano, C. (1992) Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy. Eur Urol 21: pp. 309-14
- Rhodes, L., Primka, R.L., Berman, C. (1993) Comparison of finasteride (Proscar®), a 5-α reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5-α reductase inhibition. Prostate 22: pp. 43-51 CrossRef
- Andersson, S., Russell, D.W. (1990) Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reduc-tases. Proc Natl Acad Sci USA 87: pp. 3640-4 CrossRef
- Jenkins, E.P., Andersson, S., Imperato-McGinley, G. (1992) Genetic and pharmacological evidence for more than one human steroid 5α-reductase. J Clin Invest 89: pp. 293-300 CrossRef
- Andersson, S., Berman, D.M., Jenkins, E.P. (1991) Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature 354: pp. 159-61 CrossRef
- Bonnet, P., Reiter, E., Bruyninx, M. (1993) Benign prostatic hyperplasia in normal prostate aging: differences in types I and II 5 alpha reductase and steroid hormone receptor messenger ribonucleic acid (mRNA) levels but not in insulin like growth factor mRNA levels. J Clin Endocrinol Metab 77: pp. 1203-8 CrossRef
- Hirsch, K.S., Jones, C.D., Audia, J.E. (1993) LY191704: a selective, nonsteroidal inhibitor of human steroid 5α-reductase type 1. Proc Natl Acad Sci USA 90: pp. 5277-81 CrossRef
- Iehlé, C., Raynaud, J.-P., Martin, P.-M. (1996) Steroid 5α-reductase type 1 is expressed in the human pathological prostate [abstract]. J Urol 155: pp. 808
- Rennie, P.S., Bruchovsky, N., McLaughlan, M.G. (1983) Kinetic analysis of 5α-reductase isoenzymes in benign prostatic hyperplasia (BPH). J Steroid Biochem 19: pp. 169-73 CrossRef
- Ross M, Chapman K, Habib FK. The expression of type 1 and type 2 5-alpha reductase mRNA in BPH and prostate cancer and in short term primary cultures of prostate epithelial and stromal cells [abstract]. British Prostate Group: Future Perspectives in Prostatic Disease; 1996; 19-20 Mar; The University of York, UK, p 22.
- Levine, A.C., Wang, J.-P., Ren, M. (1996) Immunohistochemical localization of steroid 5α-reductase 2 in the human male fetal reproductive tract and adult prostate. J Clin Endocrinol Metab 81: pp. 384-9 CrossRef
- Habib F, Grant E. BPH and current biochemical trends. In press
- Silver, I., Wiley, E.L., Davis, D.L. (1994) Expression and regulation of steroid 5α-reductase 2 in prostate disease. J Urol 152: pp. 433-7
- Silver, I., Wiley, E.L., Thigpen, A.E. (1994) Cell type specific expression of 5α-reductase 2. J Urol 152: pp. 438-42
- Thigpen, A.E., Silver, R.I., Guileyardo, J.M. (1993) Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J Clin Invest 92: pp. 903-10 CrossRef
- Tsai, S.Y., Tsai, M.-J., O’Malley, B.W. The steroid receptor super-family: transactivators of gene expression. In: Parker, M.G. eds. (1991) Nuclear hormone receptors. Academic Press, London, pp. 103-24
- Ravenna L, Di Silverio F, Russo M, et al. Effects of the lipido-sterolic extract of Serenoa repens (Permixon®) on human pro-static cell lines. Prostate. In press
- Robinette, C.L. (1988) Sex-hormone-induced inflammation and fibro-muscular proliferation in the rat lateral prostate. Prostate 12: pp. 271-86 CrossRef
- Theyer, G., Kramer, G., Assmann, I. (1992) Phenotypic characterization of infiltrating leukocytes in benign prostatic hyper-plasia. Lab Invest 66: pp. 96-107
- Paubert-Braquet M, Richardson FO, Servent-Saez N, et al. Effect of Serenoa repens extract (Permixon®) on estradiol/tes-tosterone-induced experimental prostate enlargement in the rat. Pharmacol Res. In press
- Stenger, A., Tarayre, J.-P., Carilla, E. (1982) Pharmacologic and biochemical study of the hexane extract of Serenoa repens B (PA 109). La Gazette Médicale de France 89: pp. 2041-8
- Bernardi di Valserra, M., Tripodi, A.S., Contos, S. (1994) Serenoa repens capsules: a bioequivalence study. Acta Toxicol Ther 15: pp. 21-39
- Oesterling, J.E. (1995) Benign prostatic hyperplasia. Medical and minimally invasive treatment options. N Engl J Med 332: pp. 99-109 CrossRef
- Geller, J., Kirschenbaum, A., Lepor, H. (1995) Therapeutic controversies: clinical treatment of benign prostatic hyperplasia. J Clin Endocrinol Metab 80: pp. 745-8 CrossRef
- Andersen, J.T. (1995) α1-Blockers vs 5α-reductase inhibitors in benign prostatic hyperplasia: a comparative review. Drugs Aging 6: pp. 388-96 CrossRef
- Berry, S.J., Coffey, D.S., Walsh, P.C. (1984) The development of human benign prostatic hyperplasia with age. J Urol 132: pp. 474-9
- Clinton, J.J. (1994) Benign prostatic hyperplasia (BPH) — diagnosis and treatment. JAMA 271: pp. 1151 CrossRef
- Lepor, H., Nitti, V.W. (1996) Treatment of benign prostatic hyperplasia. Reply [letter]. Lancet 347: pp. 1270 CrossRef
- Authie, D., Cauquil, J. (1987) A multicenter study of the efficacy of Permixon in daily practice [in French]. C R Ther Pharmacol Clin 5: pp. 3-13
- Ebbinghaus, K.D. (1995) Efficacy of Permixon® in the treatment of benign prostatic hyperplasia [in German]. Für Urologie und Urogynäkologie 2: pp. 17-21
- Barreto, H.P., Vivero, C., Castro, L.E.C. (1995) Advances in the medical management of benign prostatic hyperplasia [in Spanish]. Tribuna Medica 91: pp. 197-205
- Hanus, M., Matouskova, M. (1993) Alternative treatment of benign prostatic hypertrophy by Permixon (Capistan) [in Czech]. Rozhl Chir 72: pp. 75-9
- Mancuso, G., Guillot, F., Migaleddu, V. (1986) Serenoa repens in treatment of benign prostate hypertrophy [in Italian]. Urologia 53: pp. 709-14
- Martorana, G., Giberti, C., Pizzorno, R. (1986) Treatment of prostate adenoma with Serenoa repens extract [in Italian]. Urologia 53: pp. 366-9
- Olle-Carreras, J. (1987) Our experience with a hexane extract of Serenoa repens in the treatment of benign prostatic hypertrophy [in Spanish]. Arch Esp Urol 40: pp. 310-3
- Orfei, S., Grumelli, B., Galetti, G. (1988) Clinical and flowmetric study of Permixon in aged patients [in Italian]. Urologia 55: pp. 373-81
- Paoletti, P.P., Francalanci, R., Tenti, S. (1986) Medical treatment of prostate hypertrophy: trial with the therapeutic use of Serenoa repens [Italian]. Urologia 53: pp. 182-7
- Pescatore, D., Calvi, P., Michelotti, P. (1986) Urodynamic evaluation of management of prostatic adenoma with Serenoa repens extract [in Italian]. Urologia 53: pp. 894-7
- Pisani, E. (1985) National experience on therapeutic use of Serenoa repens. New Trends Androlog Sci 1: pp. 110-2
- Tenaglia, R., DśEramo, G., Bertolozzi, L. (1985) Mechanism of action of Serenoa repens: considerations and conclusions. New Trends Androlog Sci 1: pp. 132-4
- Vespasiani, G., Cesaroni, M., Parziani, S. (1987) Treatment of benign prostatic hypertrophy with Serenoa repens [in Italian]. Urologia 54: pp. 145-9
- Dathe, G., Schmid, H. (1991) Phytotherapy of benign prostate hyperplasia with Serenoa repens extract (Permixon registered ) [in German]. Urologe Ausg B 31: pp. 220-3
- Boccafoschi, C., Annoscia, S. (1983) Comparison of Serenoa repens extract and placebo in controlled clinical trial in patients with prostatic adenomatosis [in Italian]. Urologia 50: pp. 1-14
- Champault, G., Patel, J.C., Bonnard, A.M. (1984) A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol 18: pp. 461-2 CrossRef
- Cukier, D., Le, G. (1985) Serenoa repens extract vs. placebo. C R Ther Pharmacol Clin 4: pp. 15-21
- Descotes, J.L., Rambeaud, J.J., Deschaseaux, P. (1995) Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 9: pp. 291-7 CrossRef
- Emili, E., Cigno, M., Petrone, U. (1983) Clinical results on a new drug in the treatment of benign prostatic hyperplasia (Permixon) [in Italian]. Urologia 50: pp. 1042-9
- Reece Smith, H., Memon, A., Smart, C.J. (1986) The value of Permixon in benign prostatic hypertrophy. Br J Urol 58: pp. 36-40 CrossRef
- Tasca, A., Barulli, M., Cavazzana, A. (1985) Treatment of obstruction in prostatic adenoma using an extract of Serenoa repens. Double-blind clinical test v. placebo [in Italian]. Minerva Urol Nefrol 37: pp. 87-91
- Carraro J-C, Raynaud J-P, Koch G, et al. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1098 patients. Prostate. In press
- Grasso, M., Montesano, A., Buonaguidi, A. (1995) Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol 48: pp. 97-103
- Adriazola Semino, M., Lozano Ortega, J.L., Garcia Cobo, E. (1992) Symptomatic treatment of benign hypertrophy of the prostate. Comparative study of prazosin and Serenoa repens [in Spanish]. Arch Esp Urol 45: pp. 211-3
- Mandressi, S., Tarallo, U., Maggioni, A. (1983) Medical treatment of benign prostatic hyperplasia: efficacy of the extract of Serenoa repens (Permixon®) compared to that of the extract of Pygeum africanum and a placebo [in Italian]. Urologia 50: pp. 752-8
- Pannunzio, E., D’Ascenzo, R., Giardinetti, F. (1986) Serenoa repens vs. gestonorone caproate in treatment of benign prostatic hypertrophy [in Italian]. Urologia 53: pp. 696-705
- Peters, D.H., Sorkin, E.M. (1993) Finasteride: a review of its potential in the treatment of benign prostatic hyperplasia. Drugs 46: pp. 177-208 CrossRef
- Anon. Benign prostatic hyperplasia: diagnosis and treatment: guideline overview. J Natl Med Assoc 1994 Jul; 86: 489-549
- McCarthy, M. (1994) BPH guidelines. Lancet 343: pp. 473
- Eri, L.M., Tveter, K.J. (1995) α-Blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 154: pp. 923-34 CrossRef
- Madsen, F.A., Bruskewitz, R.C. (1995) Benign prostatic hyperplasia: pathophysiology and pharmacological treatment. Curr Opin Nephrol Hypertension 4: pp. 455-9 CrossRef
- Lepor, H., Williford, W.O., Barry, M.J. (1996) The efficacy of ter-azosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 335: pp. 533-9 CrossRef
- Walsh, P.C. (1996) Treatment of benign prostatic hyperplasia [editorial]. N Engl J Med 335: pp. 586-7 CrossRef
- Serenoa repens (Permixon®)
Drugs & Aging
Volume 9, Issue 5 , pp 379-395
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors